Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 91-100 of 314 for infectious diseases

Edit search filters
  1. Early Fluconazole Treatment for Coccidiodomycosis Pneumonia

    Scottsdale/Phoenix, AZ

  2. A Study of the Effect of Ixazomib on the Reservoir of T Cells Infected with HIV DNA

    Rochester, MN

  3. Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

    Scottsdale/Phoenix, AZ

  4. Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papillomavirus-Related Cancer in Adult Women After Kidney Transplant

    Rochester, MN

  5. Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients

    Rochester, MN

  6. Trial of Obeticholic Acid in Patients with Moderately Severe Alcoholic Hepatitis (AH)

    Rochester, MN

  7. An Expanded Access Study of Sofosbuvir Combined with Ribavirin and Either with or without Pegylated Interferon for Treating Aggressive Post-Transplant Hepatitis C

    Jacksonville, FL

  8. Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment

    Rochester, MN

  9. Analytic Treatment Interruption (ATI) to Assess HIV Cure

    Rochester, MN

  10. A Study to Compare the Effectiveness and Safety of ABT-493/ABT-530 to Sofosbuvir Given Together with Declatasvir in Adults with a Chronic Hepatitis C Virus Infection

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer